Clastogenicity of selective serotonin-reuptake inhibitors

• Published in: Mutation research. Genetic toxicology and environmental mutagenesis 2004-03, Vol.558 (1), p.137-144
• Main Authors: Bozkurt, Gokay, Abay, Ercan, Ates, Ibrahim, Karabogaz, Goksel, Ture, Mevlut, Savran, Fatma Oguz, Palanduz, Sukru, Temocin, Kubra, Algunes, Cetin
• Format: Article
• Language: English
• Subjects: Biological and medical sciences; Cells with high-frequency sister chromatid exchanges (HFC); Chromosome aberration; Fundamental and applied biological sciences. Psychology; Genetics of eukaryotes. Biological and molecular evolution; Indicator for detecting clastogenicity; Medical sciences; Selective serotonin-reuptake inhibitors; Sertraline; Sister chromatid exchanges; Toxicology
• ISSN: 1383-5718; 1879-3592
• DOI: 10.1016/j.mrgentox.2003.11.005

Objective: Selective serotonin-reuptake inhibitors (SSRIs) are used in the treatment of various forms of psychiatric disorders. Preclinical studies in laboratory animals have indicated that SSRIs were not genotoxic, but clear results from in vitro testing of SSRIs in a human cell system are currently scarce. The purpose of this study was to investigate whether SSRIs might be genotoxic. Sertraline was chosen as model SSRI, since it appears to be at least as well-tolerated as other SSRIs and may even have a more favourable side-effect profile. Unlike fluoxetine, fluvoxamine and paroxetine, sertraline has low potential for pharmacokinetic drug interactions. So, sertraline would be considered first in the treatment of psychiatric disorders requiring SSRI therapy in the future. We therefore examined peripheral lymphocytes from sertraline-treated patients for both sister chromatid exchanges (SCEs), cells with a high frequency of SCEs (HFC) and chromosome aberrations (CA) to evaluate the clastogenicity of SSRIs. Method: Ten sertraline-treated patients meeting ‘Structured Clinical Interview for DSM-IV’ criteria for both generalized anxiety disorder and major depression were compared with 18 healthy volunteers and 18 non-treated patients with similar psychopathology. Sertraline hydrochloride was administered orally at 50 mg daily for 10 months to 1 year. The participants were selected on the basis of similar responses to a questionnaire assessing risk of genotoxicity related to other aspects of life. All participants had very similar lifestyles, medical histories, biological and dietary factors. All subjects were non-smokers. Result: A statistically significant difference between patients with both generalized anxiety disorder and major depression (sertraline-treated or non-treated) and healthy volunteer groups was found by both SCE frequencies and HFC percentages. Both patient groups showed higher frequencies of SCEs than the healthy controls. No statistically significant difference was found between SCE frequencies or HFC percentages observed in sertraline-treated and non-treated patient groups. No statistical difference was found between groups with respect to the frequency of CA. Conclusion: There are no adequate studies analysing the clastogenicity of SSRIs, in particular of sertraline. The SCE frequency, the percentage HFC and the frequency of CA in patients with both generalized anxiety disorder and major depression exposed to daily doses of sertraline do no